Select your language
A phase II study of TPEx (taxotere-platinum-cetuximab) followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN).
Coordinator : Caroline Even
Start date : december 2024
Expected number of patients : 70
Access detailed information on the trial in the private section
OSKAR
(trial promoted by MSD in exclusive partnership with GORTEC)
Real-World Use Of Pembrolizumab In Patients With Unresectable Recurrent or Metastatic Head and Neck Cancer In France : A Prospective Non-Interventional Multicentric Study linked to the French Health System Database
Coordinator : Caroline Even
Start date : january 2023
Expected number of patients : 236 (118 per cohort)
Access detailed information on the trial in the private section
AdCC (2023-01)
Trial closed to inclusions
Phase Ib study of OBT076 or OBT076 followed by Balstilimab in patients with recurrent or metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N).
Start date : 2023
Expected number of patients: 38
Access detailed information on the trial in the private section
XXL (2022-01)
Trial closed to inclusions
A double-blind, randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin.
Coordinator : Prof. BOURHIS
Start date : 2023
Expected number of patients: 538
Access detailed information on the trial in the private section
TPFmORL (GORTEC 2019-01)
Trial closed to inclusions
Randomized phase II study comparing induction chemotherapy combining cisplatin, 5-Fluorouracil and docetaxel at modified doses (TPFm) or standard doses (TPF) in patients with locally advanced squamous cell ENT cancer
Coordinator : Dr Fayette
Start date : 2020
Expected number of patients: 99
Access detailed information on the trial in the private section
REWRITe (GORTEC 2018-02)
Trial closed to inclusions
A phase II trial evaluating radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : 2019
Expected number of patients : 73
Access detailed information on the trial in the private section
NIVO POST OP (GORTEC 2018-01)
Trial closed to inclusions
Phase III randomized trial of post-operative adjuvant nivolumab and concomitant cisplatin-radiotherapy (standard of care) in patients with locally advanced resected squamous cell carcinoma of the head and neck (SCCHN) at high risk of recurrence
Coordinator : Prof. BOURHIS
Start date : 2020
Expected number of patients : 680 (340 per arm)
Access detailed information on the trial in the private section
FRAILIMMUNE (GORTEC 2018-03)
Trial closed to inclusions
Multicenter, prospective, single-arm phase II study evaluating the efficacy and safety of Durvalumab with Carboplatin and Paclitaxel as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck not eligible for standard chemotherapy
Coordinator : Dr Fayette
Start date : 2019
Expected number of patients : 102
Access detailed information on the trial in the private section
STEREO-POSTOP (GORTEC 2017-03)
Trial closed to inclusions
Multicenter, phase II study of postoperative hypofractionated stereotactic radiotherapy in the treatment of localized oropharyngeal and oral cavity cancers with high risk margins
Coordinator : Dr Biau
Start date : 2018
Expected number of patients : 90
Access detailed information on the trial in the private section
SIMPA 01 (GORTEC 2017-02)
Trial closed to inclusions
Double-blind, multicenter, phase III study evaluating the efficacy of an oral immune modulating formula on survival during postoperative concomitant chemo-radiotherapy in head and neck squamous cell carcinoma
Coordinator : Dr Senesse
Start date : 2019
Number of patients : 28
Access detailed information on the trial in the private section
REACH (GORTEC 2017-01)
Trial closed to inclusions
Phase III randomized trial of avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : 2017
Expected number of patients : 688
Access detailed information on the trial in the private section
Phase III randomized trial of chemo-radiotherapy versus radiotherapy alone in the treatment of sinus and salivary gland tumors
Coordinator : Dr François-Régis FERRAND
Start date : 2017
Expected number of patients : 260 (130/arm)
Access detailed information on the trial in the private section
PembroRad (GORTEC 2015-01)
Trial closed to inclusions
Phase II randomized study to determine the tolerance and efficacy of Pembrolizumab or Cetuximab combined with radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Coordinator : Prof. BOURHIS
Start date : 2016
Expected number of patients : 132 patients (66 per arm)
Access detailed information on the trial in the private section
OMET (GORTEC 2014-04)
Trial closed to inclusions
Role of stereotactic radiotherapy in patients with oligometastases.
Coordinator : Prof. Sun
Start date : 2015
Expected number of patients : 78 (39 per arm)
Access the Clinical Trials link
Access detailed information on the trial in the private section
SALTORL (GORTEC 2014-03)
Trial closed to inclusions
Assessment of survival without laryngeal-esophageal dysfunction after 2 years in patients with resectable carcinoma of the larynx or hypopharynx.
Coordinator: Prof. Calais
Start date : 2015
Expected number of patients : 256
Access the Clinical Trials link
Access detailed information on the trial in the private section